003) ▪ Evaluating the benefits of second-generation antivirals (gastroenterologists, n = 28: 7% vs 50%, P= .008; PCPs, n=198: 17% vs 55%, P < .001) ▪ Accurately staging liver disease (PCPs, n=212: 32% vs 44%, P = .04) ▪ Identifying predictors of virologic Alectinib cell line response (PCPs, n=266: 47% vs 66%, P<.001) ▪ Distinguishing between indications for near-term treatment vs treatment deferral (PCPs, n=198: 51% vs

78%, P<.001) ▪ Managing side-effects for patients on protease-inhibitor-based triple therapy (gastroenterologists, n=30: 13% vs 37%, P=.001; PCPs, n=133: 8% vs 46%, P<.001) ▪ Appropriate use of treatment futility rules for patients on protease-inhibitor-based triple therapy (PCPs, n=266: 30% vs 54%, P< .001) Conclusion: This personalized learning curriculum guided physicians through a defined sequence of CME interventions to significantly improve physician performance across several different practice gaps in chronic HCV care. Disclosures: Nancy Reau - Advisory Committees or Review Panels: Kadmon, Jannsen, Vertex, Idenix, AbbVie, Jannsen; Grant/Research Support: Vertex, Gilead, Genentech, AbbVie, BMS, Jannsen, BI Catherine C. Capparelli - Stock Shareholder: Gilead

Sciences The following people have nothing to disclose: Tara G. Edmonds, Jennifer Garick, Simi Hurst Purpose: While emerging literature suggests that the Emergency Department (ED) is an ideal venue for Hepatitis C (HCV) screening among US Baby Boomers, little research has described subsequent follow-up and linkage after a positive Rapamycin in vivo HCV antibody (Ab) result in this setting. In this investigation, we studied follow-up contacts, completed referrals, and linkage to care in a cohort of patients from a large opt-out screening program in the South. Methods: We evaluated Baby Boomers who were screened for HCV at an urban academic ED during a four month period (9/13-12/13) using data

from ED electronic medical records and linkage tracking software. ED providers delivered positive results at point of care, and a project outreach coordinator initiated follow-up phone contacts with all Ab positive persons within 7 days find more to confirm receipt of results and facilitate referrals. The primary outcomes were successful follow-up contact, referral completion (scheduled appointment with HCV provider), and linkage to care indicated by an arrived HCV provider visit. Results: Of 294 persons with an initial reactive HCV Ab result (11.6% prevalence), two-thirds (n=169, 68.1%) had chronic infection based on RNA confirmatory testing. Among those RNA-positive, 71% were male, 60% minority race, 39% uninsured, and 42% had publicly funded insurance. During the six-month period following screening, we made 487 follow-up call attempts (mean = 2.9 per RNA positive individual), successfully contacting 59.2% overall. Contact success was higher for females than males (77.6% vs. 53.3%, p=0.01). Half (52.